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The potential of PACE4 as a pharmacological target in prostate cancer has been demonstrated as this proprotein
convertase is strongly overexpressed in human prostate cancer tissues and its inhibition, using molecular or
pharmacological approaches, results in reduced cell proliferation and tumor progression in mouse tumor
xenograft models. We developed a PACE4 high-affinity peptide inhibitor, namely, the multi-leucine (ML), and
sought to determine whether this peptide could be exploited for the targeting of prostate cancer for diagnostic or
molecular imaging purposes. We conjugated a bifunctional chelator 1,4,7-triazacyclononane-1,4,7- triacetic acid
(NOTA) to the ML peptide for copper-64 (64Cu) labeling and positron emission tomography (PET)– based prostate
cancer detection. Enzyme kinetic assays against recombinant PACE4 showed that the NOTA-modified ML peptide
displays identical inhibitory properties compared to the unmodified peptide. In vivo biodistribution of the 64Cu/
NOTA-ML peptide evaluated in athymic nude mice bearing xenografts of two human prostate carcinoma cell lines
showed a rapid and high uptake in PACE4-expressing LNCaP tumor at an early time point and in PACE4-rich
organs. Co-injection of unlabeled peptide confirmed that tumor uptake was target-specific. PACE4-negative
tumors displayed no tracer uptake 15 minutes after injection, while the kidneys, demonstrated high uptake due to
rapid renal clearance of the peptide. The present study supports the feasibility of using a 64Cu/NOTA-ML peptide
for PACE4-targeted prostate cancer detection and PACE4 status determination by PET imaging but also provides
evidence that ML inhibitor–based drugs would readily reach tumor sites under in vivo conditions for
pharmacological intervention or targeted radiation therapy.
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Prostate cancer is the most prevalent cancer among men and is the second
leading cause of cancer deaths inNorthAmericanmen [1]. Like the detection
of primary tumors and subsequentmetastases, the lack of novel approaches to
improve aggressive prostate adenocarcinoma diagnosis is part of the
important challenge that needs to be overcome for effective prostate cancer
management. In the last two decades, diagnostic imaging using positron
emission tomography (PET) has proven itself to be a useful tool for
tumor and metastasis detection and assessment of treatment responses.
Such modalities are met with the widely used radiolabeled metabolic
PET tracer [18F]-fluoro-2-deoxy-D-glucose ([18F]-FDG) [2]. However,
for several indications including prostate cancer, [18F]-FDG does not
provide sufficient limit of detection due to low tumor avidity for this
tumor type, which renders imaging difficult and furthermore does not
allow tumor grading or discrimination of benign prostate hyperplasia
[3–6]. The use of target-specific PET imaging is an emerging way to
overcome these issues and to generate novel radiopharmaceuticals for
prostate cancer detection but also for molecular diagnostic as target-
specific probe allows tumor target status determination [7,8]. Still new
target discovery remains a challenge, and the use of overexpressed
proteins documented as pharmacological targets offers interesting
possibilities for molecular imaging probe development, especially when
inhibitors are available. In this context, molecular imaging also broadens
the array of information as it can encompass tumor target status and
define further treatment possibilities for each specific case analyzed,
such as in personalized medicine approaches.
We recently reported the overexpression of the protease PACE4 in
prostate cancer specimens [9]. Additionally, Oncomine (Compendia
Bioscience, Ann Arbor, MI) resources, as well as two recent studies
[10,11], shows that PACE4 overexpression is observed in 90% to
95% of examined prostate tumors, correlating with aggressiveness.
PACE4 is a member of the mammalian proprotein convertase (PC)
family of enzymes that includes eight proteolytically active members,
namely, furin, PC1/3, PC2, PC4, PC5/6, PC7, PACE4, and SKI-1/
S1P [12–14]. PCs carry out their proteolytic processing functions in
cell secretory pathways and are reported for their central role in cancer
as their substrates include many cancer-related proteins that require
an activation step before gaining their full biologic functions [15,16].
PACE4 localizes both within and outside the cells, either in the
secretory pathways [17,18] or at the cell surface within the
extracellular matrix [19,20]. Through molecular silencing studies
we demonstrated the importance of PACE4 in prostate cancer
progression, especially through its role in cancer cell proliferation,
growth factor activation, tumor growth, and neovascularization,
making the case for PACE4 as a pharmacological target in prostate
cancer [9,21]. These findings led our group to the development of a
high-affinity octapeptide inhibitor targeting PACE4 with considerable
selectivity, namely, the multi-leucine (ML) peptide, Ac-LLLLRVKR-
NH2 [22]. ML treatment phenocopies PACE4 knockdown leading to
reduced proliferation and G0/G1 blockade of cell cycle progression in
prostate cancer cells [12]. As small peptides are extremely valuable
scaffolds for the generation of bioconjugated imaging probes [23], we
hypothesized that this high-affinity inhibitor could be suitable for
prostate cancer tumor detection as its target is highly expressed in
prostate neoplasia, especially in basal and stromal cells [11,24].
We therefore generated a PET suitable radiolabeled form of the
ML peptide by the conjugation of a 1,4,7-triazacyclononane-1,4,7-
triacetic acid (NOTA) chelating group at the N-terminal extremity
that can further be quickly and efficiently used to generatepositron emitter with a low positron energy (Eβ+) of 656 keV that
ensures high-resolution imaging [25] and a half-life of 12.7 hours.
64Cu can also be readily produced using a medical cyclotron, thus
combining multiple advantages for molecular imaging [26]. In the
present study, we demonstrate that the NOTA-conjugated PACE4
inhibitor maintains its affinity toward PACE4 enzyme using kinetic
assays and distributes in PACE4-rich organs and within LNCaP
prostate cancer xenografts, as supported by competition studies with
unlabeled peptide co-injections. This supports the potential of
PACE4 as a reachable target for prostate cancer detection but also for
pharmacological intervention with such inhibitory compounds. The
ability of the peptide to target the tumor could also provide novel
information on tumor status, such as to profile tumor targets for
availability in theranostic or personalized medicine applications.
Materials and Methods
Materials and Reagents
All solvents used were HPLC grade and used without further
purification. TentaGel S RAM resin (0.22mmol/g) was purchased from
Rapp Polymere (Tübingen, Germany). All the amino acid derivatives
and coupling reagents were purchased from ChemImpex International
(Wood Dale, IL). Piperidine was obtained from A&C American
Chemicals Ltd (Saint-Laurent, Québec). 1,4,7-Triazacyclononane was
purchased from CheMatech (Dijon, France). All other reagents were
purchased from Sigma-Aldrich (St Louis, MO). Preparative HPLC was
carried out using aWaters Delta Prep 3000module with a Gemini C18
(10 μm, 250 × 30 mm) column. HPLC–mass spectrometry (MS)
purity and characterization analyses were performed on a Waters
Alliance 2695 separation module coupled with a Micromass ZQ 2000
mass spectrometer equipped with an analytical column XBD-Eclipse
plus C18 (1.8 μm, 3 × 50 mm). Ulta Performance Liquid
Chromatography (UPLC) analyses were carried out on Acquity
UPLC CLASS (Waters, Milford, MA) using an Acquity UPLC BEH
C18 column (1.7 μm, 2.1 × 50 mm) with either an Evaporating Light
Scattering Detector (ELSD) detector or a radioactive detector (Bioscan
photomultiplicator tube BFC-3200). The columnwasheated at 50°Cand
the analysis method used was a 15-minute gradient from 0% to 100%
acetonitrile (ACN; 0.5 ml/min; 0.025% acetic acid). High-resolution MS
(HR-MS; TripleTOF 5600; ABSciex, Foster City, CA) was also performed
to confirm the identity of the pure products. According to HPLC,MS, and
HR-MS, the purity of peptides exceeded 97%. Their physicochemical
properties are presented in Table S1.
Peptide Synthesis
The peptide synthesis was performed on an automated system
using Tentagel S RAM resin. Unless otherwise stated, all reactions
were performed under nitrogen atmosphere. Water-sensitive reactions
were performed in anhydrous solvents. N,N′-dimethylformamide
(DMF) was dried over molecular sieves for 1 week before use. The
resin was first loaded in the reaction column of the automatic peptide
synthesizer (Pioneer Peptide Synthesis System; Applied Biosystems,
Foster City, CA), and Fmoc amino acids were added in a three-fold
excess using HATU in the presence of N,N-diisopropylethylamine. A
deprotection step was performed using 20% piperidine in DMF. The
NOTA chelate unit was synthesized using the procedure described by
our group [27]. The N-terminal Fmoc was cleaved from the peptidyl
resin using 50% piperidine for 30 minutes, followed by successive
636 PACE4-Based Molecular Targeting of Prostate Cancer Couture et al. Neoplasia Vol. 16, No. 8, 2014washingwithDMF twice, dichloromethane (DCM) thrice, isopropanol,
DCM, isopropanol, DCM, isopropanol, and DCM thrice. The resin
was then treated with 2.5-fold equivalent of bromoacetic anhydride
[preformed in DCM with diisopropylcarbodiimide (2.5 equivalents)
and bromoacetic acid (5 equivalents), 15 minutes] for 30 minutes and
then was washed as before. The resin was then suspended in DCM, and
five-fold excess of 1,4,7-triazacyclononane was added followed by
shaking for 3 hours before washing and suspending in N-methyl-2-
pyrrolidone (NMP). t-Butyl bromoacetate (3 equivalents) was added
and shaken for 2 hours before washing. The peptide was cleaved from
the polymer solid support using a mixture of trifluoroacetic acid (TFA)/
H2O/triisopropylsilane (95/2.5/2.5, vol/vol/vol) and stirred for 3 hours.
The mixture was filtered, and the filtrate was precipitated in diethyl
ether. After centrifugation and solvent decantation, the crude peptide
was dissolved in a mixture of water and ACN, filtered, diluted in water,
lyophilized, and then purified using preparative HPLC. The identity of
the peptide was confirmed by MS and HR-MS.
Peptide Radiolabeling
The EBC-TR-19 cyclotron facility provides 64Cu isotope on a
routine basis for research purposes, using a target system developed in
collaboration with Advanced Cyclotron Systems Inc (Richmond,
British Columbia). 64Cu was prepared following the 64Ni(p,n)64Cu
reaction using an enriched 64Ni target electroplated on a rhodium
disk [28]. [64Cu]CuCl2 was recovered from the target following the
procedure described in McCarthy et al. [29] and converted to [64Cu]
Cu[II] acetate ([64Cu]Cu(OAc)2) by dissolving the [
64Cu]CuCl2 in
ammonium acetate (0.1 M; pH 5.5). Peptide was labeled with 64Cu
following conditions optimized in our laboratory [30]. Briefly, the
peptide (5 μg) was dissolved in ammonium acetate buffer (0.1 M, pH
5.5) with [64Cu]Cu-(OAc)2 (300-370 MBq; 8-10 mCi) in a total
volume of 300 to 350 μl. The resulting solution was incubated at
95°C for 10 minutes. The material was further diluted with water
(5 ml) and applied on a C18 Sep-Pack Column (Waters) to eliminate
unchelated 64Cu. Radiopeptide preparation was washed with 10 ml
of water and eluted with 3 ml of ACN containing 0.025% TFA. The
peptide fraction was collected, evaporated, and counted in a Capintec
radioisotope calibrator (Capintec, Inc, Ramsey, NJ) to calculate the
specific activity of the product. The resulting 64Cu/NOTA-ML.
peptide was reconstituted in phosphate-buffered saline (PBS) at pH
7.4. Full peptide labeling was routinely assessed. Fluorine-18 was
prepared by the 18O(p,n)18 F reaction on 18O enriched water as
target material using the EBC-TR-19 cyclotron facility following
established procedures and used for [18F]-FDG synthesis as described
in Hamacher et al. [31].
In Vitro Kinetic Assays
PACE4 enzyme kinetic assays were performed using the fluorogenic
substrate Pyr-Arg-Thr-Lys-Arg-methyl-coumaryl-7-amide (100 μM;
Bachem, Torrance, CA.) in 20 mM bis-Tris (pH 6.5), 1 mM CaCl2,
and 1.8 mg/ml BSA. Purified human recombinant PACE4 was
obtained as described previously in Fugère et al. [32]. Assays were
carried out at 37°C during 60 minutes, and real-time fluorescence was
measured using a Gemini EM 96-well spectrofluorometer (Molecular
Devices, Sunnyvale, CA; λEM = 370 nm; λEX = 460 nm; cutoff = 435
nm) as described in Levesque et al. [22]. Increasing concentrations of
peptide were assayed to perform a competitive inhibition assay
measured by substrate cleavage inhibition. Kinetics assays were analyzed
using SoftMax Pro 5, and inhibitory constant (Ki) values weredetermined from IC50 using Cheng and Prusoff equation with 3.5
μM as PACE4 Km.
Cell Culture and Human Tumor Xenograft Models
LNCaP and PC3 human prostate cancer cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA) and were
maintained in Roswell Park Memorial Institute medium (RPMI
1640) supplemented with 10% FBS (Wisent Bioproducts, St Bruno,
Québec). PACE4 knockdown LNCaP were cultivated as described
previously [21]. Cells were grown at 37°C in a water-saturated
atmosphere with 5% CO2. Cells were grown in complete media and
harvested at their exponential growing state. Four- to 6-week-old
male athymic nude mice (Nu/Nu; Charles River Laboratories,
LaSalle, Québec) were inoculated subcutaneously on the shoulders
with a suspension of 1 × 106 PC3 cells in 100 μl of PBS or on the
hips with 2.5 × 106 LNCaP cells in 200 μl of ice-cold PBS/
Matrigel (1:1; BDBiosciences, Bedford,MA).Mice were housed under
pathogen-free conditions and the inoculations were done under
isoflurane anesthesia in a sterile laminar flow hood. Tumors were
given a minimum of 4 weeks to grow to a minimal diameter of 5 mm
before being used for biodistribution or PET imaging studies. All
animal studies were conducted in compliance with the Canadian
Council on Animal Care guidelines and with the approval of the Animal
Care Committee of the Université de Sherbrooke.
Cell Uptake
For cell uptake experiments, 2.5 × 105 cells were seeded into 12-well
plates 48 hours before the experiments were performed. Culture medium
was replaced by fresh serum-freemedium, and 180 to 200 kBq (5μCi; 25
μl) of 64Cu/NOTA-ML were added to each well. After incubation, cells
were washed three times with PBS and lysed using 10% sodium dodecyl
sulfate. Cell lysate radioactive content was measured in a gamma counter
(Cobra II auto-gamma counter; Packard, Minneapolis, MN). Precise cell
counts (Trypan blue stain) were determined on mirror plates following
the washing procedure. The results were expressed as percentage of the
peptide dose per 106 cells.
In Vivo Stability Studies
For stability studies, the 64Cu-radiolabeled peptide reconstituted in
PBS [20-30 MBq (500-800 μCi); 100 μl] was injected to air/
isoflurane-anesthetized CD1 (Charles River Laboratories) mice through
the caudal vein. Fifteen and 30 minutes following injection, blood was
collected and centrifuged, and plasma protein precipitation with ACN
(two volumes: 70% final concentration) followed. Samples were
analyzed by UPLC with a radioactivity detector and retention times
(RTs) were compared to the original radiolabeled peptide to monitor
peptide integrity. For radio-thin layer chromatography (radio-TLC),
blood was spotted directly on C18 TLC plates and sodium citrate buffer
(0.1 M, pH 5.5) was used as a developing solvent. Image capture was
performed on an Instant Imager scanner (Bioscan, DC Washington).
In Vivo Biodistribution
Biodistribution studies were performed by injecting 400 to 900
kBq (10-25 μCi; 100 μl) of 64Cu-NOTA-ML to isoflurane-
anesthetized mice (either CD1 or tumor-bearing Nu/Nu mice)
through the caudal vein. Doses were prepared and measured with a
CRC-35R dose calibrator (Capintec, Inc). Fifteen minutes post-
injection, the animals were killed by CO2 inhalation. Organs of
interest were further collected, washed, weighed, and measured in a
gamma counter. The results were expressed as percentage of the
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Figure 1. NOTA-LLLLRVKR-NH2 in vitro affinity toward PACE4.
(A) Structure of the 64Cu-NOTA-LLLLRVKR-NH2. (B) PACE4 com-
petitive enzyme kinetic assay with the cleavable fluorogenic
substrate; Pyr-Arg-Thr-Lys-Arg-methyl-coumaryl-7-amide using in-
creasing doses of both NOTA-ML and Ac-ML inhibitors. The
presented plot is a representative experiment where Vo is the
velocity of reaction in RFU/s. (B) Peptide Ki against recombinant
PACE4. Data aremean±SD (n=3). *Data fromLevesque et al. [22].
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were performed with co-injections of 0.1 μmol of unlabeled peptide
(without 64Cu chelated) to evaluate target-specific accumulation of
the peptide. Experiments were realized with a minimum of three mice
per group.
PET Imaging
PET scans were performed using a LabPET8 (Gamma Medica-
IDEAS Inc., Sherbrooke, Quebec, Canada) small animal scanner with
an axial field of view of 7.5 cm. Xenografted Nu/Numice were injected
with 3.7 to 7.4 MBq (100-200 μCi; 100 μl) of 64Cu-NOTA-
LLLLRVKR-NH2 (with or without co-injections of 0.1 μmol of
unlabeled peptide) through the caudal vein under isoflurane anesthesia.
Animal temperature was stabilized using a heated bed and monitored
using a rectal probe. For [18F]-FDG tumor uptake assessment, 15MBq
(400 μCi; 100 μl) was injected. Each animal had a 20-minute dynamic
scan immediately after compound injection. For cold peptide
competition by co-injection, the same mice were reimaged after total
radioactivity decay with both labeled and unlabeled peptides (0.1μmol)
injected together as a co-injection. The images were reconstructed by a
three-dimensional MLEM algorithm implementing an analytically
derived systemmatrix [33]. Regions of interest were traced for organs of
interest and the respective activity was derived and reported to the
injected dose per cubic centimeter of tissue for percentage calculation.
Statistical Analysis
All experiments were repeated at least three times (n = 3), and the
results were expressed as mean ± SEM if not stated otherwise. Statistical
analyses were done using Student’s t test to calculate P values.
Results
Peptide Synthesis
The ML peptide was synthesized by solid-phase automated
synthesis with Fmoc amino acids followed by manual synthesis of
the NOTA chelating moiety as described previously [27]. After
purification (N97% purity), peptide identity was confirmed by MS
and HR-MS. Information regarding the analytical characterization of
the obtained peptide is provided in Table S1. N-terminal extremity
was favored on the basis of the previous observations that N-terminal
modifications of the ML peptide (e.g., fluorescein isothiocyanate
addition, alkylation, or PEGylation) were previously done without
affecting the inhibitor potency toward PACE4 [22]. Using these
fluorescent trackable analogs, peptide entry within cells was evaluated
and found to readily penetrate within cells by its hydrophobic nature.
The peptide (Figure 1A; Molecular Weight calculated = 1294, found =
1294 g/mol) was purified by HPLC to a purity of N97% and further
used as starting material for each labeling with 64Cu.
NOTA-Coupled ML Peptide Retains Original PACE4 Affinity
and Is Retained in Prostate Cancer Cells Expressing PACE4
Unlabeled NOTA-ML peptide was first assayed against recombi-
nant human PACE4 to assess that peptide intrinsic affinity for
PACE4 was maintained despite the addition of the chelating group at
the N-terminal extremity. Enzyme kinetic assay monitored by the
cleavage of the fluorogenic substrate Pyr-Arg-Thr-Lys-Arg-methyl-
coumaryl-7-amide (Figure 1, B and C) shows that both acetylated
(Ac) and NOTA-coupled forms of the peptide display identical
inhibition potencies (Ki = 22 ± 6 and 22 ± 5 nM, respectively) toward
recombinant PACE4. To assess cell entry of the peptide in cellsin vitro, cell uptake assays were performed on LNCaP cells and their
counterparts knockdowned for PACE4 (shPACE4) [21] and compared
to the PACE4-lacking PC3 cells. Uptake was performed on 2.5 × 105
cells up to 1 hour following addition of 64Cu/NOTA-ML. Radioactive
peptide uptakes were measured within the cells following washes
(Figure 2A). Whereas PC3 cell uptake reached a plateau within the first
20 minutes, LNCaP cells kept retaining the peptide over the full
experiment as shown by the increase of the percentage of uptake over
time. PACE4 knockdown LNCaP cells displayed a reduced uptake
coherent with their attenuated levels of PACE4, as shown in Figure 2B.
The difference between the uptake of LNCaP shPACE4 and PC3 cells
is most likely attributable to the level of PACE4 distinguishing both cell
lines, the shPACE4 cells still having considerable PACE4 compared to
the PACE4-null PC3 cells.
64Cu-NOTA-ML In Vivo Stability
NOTA-ML peptide was successfully radiolabeled with 64Cu with a
yield not decay corrected greater than 95% and a specific activity of
74 to 93 TBq/mmol (2000 to 2500 Ci/mmol). As the peptide is
strictly composed of natural amino acids, in vivo stability studies were
first conducted to validate that imaging and biodistribution studies
would be performed in an appropriate time range for the tracking of
Figure 2. Peptide uptakewithin prostate cancer cells. (A) Timecourse of peptide uptake in LNCaP, PACE4 knockdownLNCaP (shPACE4), and
PC3 cells. Percentage of the peptide dose measured in the cells was reported over cell number. Data are mean ± SD (n= 3). (B) Expression
levels of PACE4 in the three cell lines determined by quantitative reverse transcription–polymerase chain reaction (data from [21]).
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CD1 mice were intravenously injected with 20 to 30 MBq of 64Cu-
NOTA-ML through the tail vein. After 15 and 30 minutes, mouse
blood samples were collected from the back paw and peptide integrity
was analyzed by UPLC coupled to a radioactivity detector (Figure 3)
and by radio-TLC (data not shown). At 15 minutes post-injection,
circulating peptide was still uncleaved (RT = 5.1 minutes; Figure 3),
whereas after 30 minutes, radioactive metabolites (RT = 3.1 and 3.9
minutes) were the main radioactive products detected in circulation.
Another interesting observation is the absence of free 64Cu in mouseFigure 3. Radiolabeled peptide integrity analysis in vivo. UPLC
analysis showing ELSD chromatogram for pure unlabeled com-
pound (black trace) and radiometric profiles of free 64Cu (red) and
radiolabeled compound after labeling (blue). The chromatograms
of plasma taken from mice 15 minutes (green) and 30 minutes
(orange) post-injection are also shown.circulating blood and the apparition of radiolabeled metabolites,
coherent with tight Cu chelation and the expected C-terminal
degradation observed in mouse plasma ex vivo in Kwiatkowska et al.
[34]. As C-terminal degradation would directly interfere with the
peptide capability to recognize PACE4 by altering the PC recognition
motif RVKR, molecular imaging beyond this window was avoided to
avoid imaging metabolites.
64Cu-NOTA-MLDistribution Is Specific to PACE4-Expressing
Tissues In Vivo
Consistent with peptide stability, biodistribution studies were
carried out on healthy CD1 mice 15 minutes post-injection, where
circulating 64Cu-radiolabeled peptide is still unaltered. Following tail
vein radiolabeled peptide injection, mice were sacrificed after
15 minutes and organs were collected to monitor radioactivity
distribution. 64Cu/NOTA-ML peptide had a very high kidney
uptake (50 ± 20%ID/g) 15 minutes post-injection. To distinguish
target-specific uptake in organs from unspecific uptake, competitive
biodistribution studies were realized with and without simultaneous
injection of 0.1 μmol of unlabeled peptide together with the
radiolabeled compound. Specific uptake can thereby be evaluated by
comparing the difference between both conditions as unlabeled
peptide molar ratio in the co-injection is greater than 500:1 (cold/
radioactive). Figure 4A presents the %ID/g determined in each
analyzed organ for both conditions in healthy mice. The data indicate
that specific accumulation is significantly higher in the liver (13 ± 2%
when unblocked vs 7 ± 1% when blocked), heart (7.4 ± 0.4% vs 4.3 ±
0.7%), and lungs (3.7 ± 0.5% vs 1.7 ± 0.2%), three known PACE4-
rich organs (see Table 1). Moderate, but still significant, target-
specific uptake was also observable in the pancreas (3.3 ± 0.1% vs 1.9 ±
0.2%), spleen (2.80 ± 0.06% vs 1.9 ± 0.2%), and bones (2.65 ±
0.09% vs 1.9 ± 0.2%).
64Cu-NOTA-ML Targets LNCaP Prostate Cancer Xenografts
and ML Does Not Accumulate in PACE4-Negative Xenografts
To further validate the hypothesis that 64Cu-NOTA-ML would
accumulate in PACE4 expressing prostate tumor, biodistribution
studies were carried out on LNCaP xenografted Nu/Nu mice. After
sacrifice 15 minutes post-injection, radioactivity levels in tumors and
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B
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Figure 4. Radiopeptide biodistribution. Biodistribution at 15minutes post-injection (A) in male CD1mice and (B) in LNCaP xenograft-bearing
Nu/Numicewith orwithout co-injection of competitive non-radiolabeled peptide. Specific uptake can be visualized as the difference between
the unblocked (−co-injection) and blocked (+co-injection) conditions. Data are mean ± SEM (n = 3). *P b .05, **P b .01.
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and illustrates a very high tumor uptake, which was blockable by
more than half of the full signal by co-injection with unlabeled
peptide (13 ± 2% vs 6 ± 2%). Peptide distribution patterns in both
mouse strains were similar with modest blocking yields (either
significant reductions or trends) in the organs with low uptake such as
pancreas, spleen, and lungs. These low blocking yields are most likely
due to the fact that PACE4 levels are low in these organs so that those
observed in these organs come mostly from unspecific peptide uptake.
Again liver-specific uptake, which was the organ with the highestTable 1. Comparison between 64Cu-NOTA-ML Target-Specific Distribution and PACE4
Reported Expression Pattern
Organs Specific Accumulation * Reported PACE4 Levels † References
Liver +++++ ++++ [47,52,53]
Heart ++++ ++++ [47,48]
Lungs +++ +++ [47,49]
Pancreas ++ +/− [54]
Spleen ++ ++ [47]
Bones ++ +/− [55,56]
Muscle + +/− [57]
Adrenals + − [47]
Adipose tissues + +/− [58]
Testis − − [47]
* Qualitative scoring based on co-injection blocking yields (difference in percentages between blocked and
unblocked conditions).
† Qualitative scoring based on reported tissue distribution; levels were estimated when possible by direct
comparison of side-by-side results. “+/−” indicates data hardly comparable.specific uptake in CD1 healthy mice (Figure 4A), was clearly
discernable in the nude mice (11 ± 1% vs 7.0 ± 0.8%).
μPET imaging was further performed on Nu/Nu mice xenografted
with LNCaP cells. Fig. 5, A and B show coronal, sagittal, and
transaxial images where tumors as well as liver uptake can be
appreciated with and without cold peptide co-injections. Kidney and
bladder were the main background sources following radiolabeled
peptide injection. As illustrated on the full mouse projections, tissues
and organs displayed low uptake and tumor uptake was clearly
discernable. Regions of interest were traced on PET images to
quantify uptake in tumors and the easily discernable organs, which are
presented in Figure 5C. These PET-derived biodistribution data
(express as %ID/cm3) are consistent with biodistribution observa-
tions (Figure 4B) and present blockable uptake in liver, heart, and
LNCaP xenografts but not in muscles and kidneys. The blockability
was easier to observe on image quantification than in the in vivo
biodistributions, most likely due to the limitation of image-specific
zone quantification in contrast to whole organs. Differences between
blocking yields (Figure 4B) are also inherent to quantification
methodologies as biodistribution data come from saline washed
organs, whereas image quantification comprises circulating compound
with the tissues.
To further demonstrate PACE4-specific uptake, PACE4-deficient
PC3 cells were used to generate tumors. PET scan imaging of these PC3
xenografted mice with 64Cu-NOTA-ML showed that PC3 xenograft
uptakes were remarkably low (more than four-fold lower as quantified
on images), as shown in Figure 6. [18F]-FDG PET scans were
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and cell viability within the tumor, which might lead to data
misinterpretation. As shown in Figure 6B, PC3 tumor [18F]-FDG
uptake was faultless, confirming that tumor accessibility was not
compromised by any means and that the peptide was able to access the
tumor. This observation also supports the fact that the absence of signal
is attributable to the lack of PACE4 in these tumor cells.
Discussion
Typical radiopeptides developed for PET imaging are cell surface
receptor radioligands, which allow the binding of circulating
molecules to receptor-expressing tumor sites and subsequent
internalization [35]. Peptides present numerous advantages over
antibodies as imaging tools due to their small size, ease of synthesis
and radiolabeling, their rapid clearance, and the possibility to attain
high specificity for their targets. Herein, we designed target-specific
PET suitable imaging probes targeting the enzyme PACE4 by the
addition of a NOTA chelating group on the N terminus of the alreadycharacterized ML peptide scaffold. Addition of such bifunctional
chelate to a peptide significantly simplify its labeling using radiometal
compared to labeling strategies using prosthetic group as single step
labeling (10 minutes) is used to obtain high specific activity [30].
In this case, enzyme targeting was based on specific and tight
interaction with PACE4 by the radiolabeled inhibitor. As previously
described [22], NOTA moiety addition, just like other chemical
modifications at the N terminus of the peptide, did not interfere with
the C-terminal PC recognition pattern nor does it lead to a significant
affinity variation toward PACE4, as assessed by enzyme kinetic assay
where the nanomolar affinity constant (Ki = 22 nM) was preserved
(Figure 1C). This is consistent with the well-characterized PC
catalytic pocket known to accommodate substrates harboring the
minimal motif RXXR. Thus, the RVKR motif within the ML peptide
is essential for PC competitive inhibition, whereas the leucine
extension is required for PACE4 selectivity [22]. When cell uptake
was evaluated, cell entry of 64Cu-NOTA-ML was coherent with
previous observation suggesting fast cell entry in a diffuse pattern
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peptide entry in cells by showing the relation between the compound
retention and PACE4 levels (Figure 2).
As the ML peptide is composed of natural amino acids, its stability
toward proteases and peptidases in biologic conditions was
predictably compromised. In vivo stability studies (Figure 3) allowed
us to establish that within 30 minutes of post-intravenous injection in
mice, the circulating peptide was considerably degraded. However, at
15 minutes post-injection, the circulating molecule remained mostly
uncleaved, indicating that further studies should be limited to no
more than 20 minutes to prevent possible misinterpretation, such as
obtaining signals that are due to metabolite accumulations. Thesein vivo stability data contrast considerably with those obtained in vitro
with the ML peptide in plasma stability assay where the peptide half-
life was 5 hours [34]. Consistent with the liver uptake, the main organ
associated with first-pass metabolism, these results suggest that either
liver or plasmatic proteases might be the main cause of 64Cu-NOTA-
ML degradation in vivo. Moreover, the fact that the observed
metabolites are still labeled with 64Cu (Figure 3) is coherent with the
expected C-terminal degradation characterized in Kwiatkowska et al.
[34].
Since PACE4 is overexpressed in prostate cancer [9], the rationale
of using a specific high-affinity PACE4 inhibitor has great potential
for the detection of prostate adenocarcinoma. LNCaP cell xenografts
were used as they are the closest cell models to human clinical prostate
adenocarcinoma [36] and because they have high PACE4 expression
levels [21,22]. As expected, radiolabeled peptide accumulation within
LNCaP tumors was relatively high and was blocked by the co-
injection of unlabeled peptide (Figures 4B and 5), indicating target-
specific competition. Additionally, it is of interest to mention that
since the competition was carried out with Cu-free peptide, the signal
shift corresponding to specific binding in co-injection is directly
related to the molecule. This discards the possibility of Cu-64Cu
competition, especially since no free 64Cu was detected in circulating
blood (Figure 3) as we previously observed in Fournier et al. [30].
Taken together, these data suggest that despite its short-term stability
in blood circulation, the peptide is capable of specifically targeting
prostate tumors, with high tumor uptake (14%; Figure 4B), and
allows their visualization by PET imaging. This is probably enabled
by the fast peptide uptake and retention by LNCaP cells, as observed
in vitro (Figure 2A). This short-term stability could be a significant
advantage for human studies, since a rapidly eliminated probe is a
general requirement in most imaging studies for rapid accumulation
at the target, not long-term period accumulation. Additionally, the
fast kidney clearance can also be considered as an advantage since it is
most likely the major contributor to the low image background,
enhancing the contrast and hence tumor visualization, especially for
distant metastasis. For further primary prostate tumor imaging in
humans, combination with either Foley catheterization or diuretic
administration should be envisioned in case of bladder signal
interference.
Additionally, the PACE4-deficient PC3 xenografts were used to
confirm peptide uptake specificity [22]. PET scans confirmed the
very low uptake of 64Cu-NOTA-ML in these xenografts (Figure 6),
lending support to the notion that this peptide could be used to
determine tumor PACE4 expression status. This point is important to
mention knowing that PACE4 expression is particularly widespread
suggesting that molecular imaging of PACE4 alone might have some
limitations. However, combined with other imaging modalities,
getting information concerning tumor PACE4 status could be
pertinent in clinical studies to distinguish prostate adenocarcinoma
that are high PACE4 expressors as these patients may be better
subjects for a PACE4-directed therapeutic intervention. PET-based
approaches have previously been used to evaluate tumor status for
estrogen receptor [37,38], EGFR (epithelial growth factor receptor)
[39], gastrin-releasing peptide receptor [30,40], and integrins [41]
using either radiolabeled antibodies or small molecule inhibitors and
short peptides, to state some examples. The present proof of concept
may be expanded since the ML peptide could be a potential
radiotracer for other PACE4 overexpressing cancers such as breast,
pancreas (as suggested by Oncomine databases), glioma [42], oral
642 PACE4-Based Molecular Targeting of Prostate Cancer Couture et al. Neoplasia Vol. 16, No. 8, 2014tongue [43], hepatocellular carcinoma [44], and ovarian cancer [45].
If true, each of these cancers could be further targeted for an anti-
PACE4 therapy regimen [46].
The tumor-specific uptake of 64Cu-NOTA-ML indicates that
systemic administration of the ML-based PACE4 targeting could be
used as a therapeutic agent. The ML peptide inhibitor has already
demonstrated important anti-proliferative properties on prostate
cancer cells [22]. Furthermore, PACE4 gene silencing has dramatic
effects on prostate cancer cells, leading to cell proliferation reduction
and tumor progression blockade with attenuated angiogenesis in vivo
[21]. While the specific uptake of the 64Cu-NOTA-ML probe in
LNCaP xenografts is very promising for imaging applications, it
remains to be seen if its therapeutic application can be equally
effective, with the most important obstacles being an important
kidney clearance and poor in vivo stability of the peptide. It is
therefore clear that future improvements in pharmacokinetic
properties, for example, through peptidomimetic modifications
and/or substitution for unnatural amino acids, are required for
in vivo pharmacological use. However, for imaging applications, such
modifications may not necessarily be beneficial, as this may result in
undesirable increased background levels.
In addition to proving itself useful for PACE4 PET imaging, the
64Cu-NOTA-ML probe also provided us with a biodistribution map
of endogenous PACE4-expressing tissues. The images obtained are
accurately mapped PACE4 biologic distribution [47]. The knowledge
of PC distribution is mainly based on mRNA expression analyses (see
Table 1). Mouse and human PACE4 proteins have a high homology
(77%), which increase to 97% when comparing solely their catalytic
domain, which is the binding domain of the ML peptide acting as an
enzymatic inhibitor, which infers species specificity of the molecule.
Aside from the pharmacokinetic limitations of the peptide and its
rapid kidney clearance (Figures 4 and 5), the obtained biodistribution
is consistent with reported expression studies, if we consider tracer
accumulation versus blocking yields in each of the analyzed organs
(Table 1). As for the brain, a PACE4-rich organ [48,49], uptake was
very low, most likely due to the inability of 64Cu-NOTA-ML probe
to reach the brain (Figure 4), because of the blood-brain barrier
impermeability to most peptides [50,51].
Conclusion
The early detection of primary prostate cancer or its metastases, as
with many other cancer types, remains an effective approach for
effective management of this disease. PACE4 overexpression in
prostate neoplastic cells represents a promising target for diagnosis
and for therapy. We have customized a PACE4-selective peptide
inhibitor for PET imaging and validated its target-specific uptake by
human prostate cancer cell xenografts. We also determined that the
radiopeptide organ distribution correlated well with endogenous
PACE4 expression. These results strongly suggest that the described
ML-based tracer is a useful tool to characterize PACE4-expressing
tumors, which in turn could lead to specific therapies. The data also
show that a pharmacological intervention with ML-based PACE4
inhibitors would likely distribute and accumulate in the tumor to
exert their anti-proliferative effects.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.07.010.
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